Targeted Delivery of GDNF through the Blood-Brain Barrier by MRI-Guided Focused Ultrasound

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Wang, Feng ^a,d   Shi, Yu ^a   Lu, Lin ^b   Liu, Li ^a   Cai, Youli ^a   Zheng, Hairong ^c   Liu, Xin ^c,e   Yan, Fei ^c   Zou, Chao ^c,e   Sun, Chengyu ^b   Shi, Jie ^b   Lu, Shukun ^a   Chen, Yun ^a  

^a PEKING UNIVERSITY SHENZHEN HOSPITAL   (China)

^b PEKING UNIVERSITY   (China)

^c SHENZHEN INSTITUTES OF ADVANCED TECHNOLOGY   (China)

^d XINXIANG MEDICAL UNIVERSITY   (China)

^e Shenzhen Key Laboratory for MRI   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AVIDIN; BIOTIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; FOCUSED ULTRASOUND; HISTOLOGY; IN VITRO STUDY; MALE; MICROBUBBLE; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; RAT; ULTRASOUND;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; DRUG DELIVERY SYSTEMS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HIGH-ENERGY SHOCK WAVES; MAGNETIC RESONANCE IMAGING; MALE; MICROBUBBLES; PC12 CELLS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84871657518     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052925     Document Type: Article

References (30)

1. Grondin R, Gash DM, (1998) Glial cell line-derived neurotrophic factor (GDNF): a drug candidate for the treatment of Parkinson's disease. J Neurol 245: P35-42.
2. Airaksinen MS, Saarma M, (2002) The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci 3: 383-394.
3. Carnicella S, Amamoto R, Ron D, (2009) Excessive alcohol consumption is blocked by glial cell line-derived neurotrophic factor. Alcohol 43: 35-43.
4. Volkow ND, Fowler JS, Wang GJ, Swanson JM, Telang F, (2007) Dopamine in drug abuse and addiction: results of imaging studies and treatment implications. Arch Neurol 64: 1575-1579.
5. He DY, Ron D, (2006) Autoregulation of glial cell line-derived neurotrophic factor expression: implications for the long-lasting actions of the anti-addiction drug, Ibogaine. FASEB J 20: 2420-2422.
6. Nevalainen N, Chermenina M, Rehnmark A, Berglof E, Marschinke F, et al. (2010) Glial cell line-derived neurotrophic factor is crucial for long-term maintenance of the nigrostriatal system. Neuroscience 171: 1357-1366.
7. Deng CX, (2010) Targeted drug delivery across the blood-brain barrier using ultrasound technique. Ther Deliv 1: 819-848.
8. Pardridge WM, (2007) Blood-brain barrier delivery. Drug Discov Today 12: 54-61.
9. Tempany CM, Stewart EA, McDannold N, Quade BJ, Jolesz FA, et al. (2003) MR imaging-guided focused ultrasound surgery of uterine leiomyomas: a feasibility study. Radiology 226: 897-905.
10. Hynynen K, McDannold N, Sheikov NA, Jolesz FA, Vykhodtseva N, (2005) Local and reversible blood-brain barrier disruption by noninvasive focused ultrasound at frequencies suitable for trans-skull sonications. Neuroimage 24: 12-20.
11. Yang FY, Fu WM, Chen WS, Yeh WL, Lin WL, (2008) Quantitative evaluation of the use of microbubbles with transcranial focused ultrasound on blood-brain-barrier disruption. Ultrason Sonochem 15: 636-643.
12. Yang FY, Lin YS, Kang KH, Chao TK, (2011) Reversible blood-brain barrier disruption by repeated transcranial focused ultrasound allows enhanced extravasation. J Control Release 150: 111-116.
13. Kaufmann BA, Lewis C, Xie A, Mirza-Mohd A, Lindner JR, (2007) Detection of recent myocardial ischaemia by molecular imaging of P-selectin with targeted contrast echocardiography. Eur Heart J 28: 2011-2017.
14. Kinoshita M, McDannold N, Jolesz FA, Hynynen K, (2006) Targeted delivery of antibodies through the blood-brain barrier by MRI-guided focused ultrasound. Biochem Biophys Res Commun 340: 1085-1090.
15. Takalkar AM, Klibanov AL, Rychak JJ, Lindner JR, Ley K, (2004) Binding and detachment dynamics of microbubbles targeted to P-selectin under controlled shear flow. J Control Release 96: 473-482.
16. Garbayo E, Ansorena E, Lanciego JL, Aymerich MS, Blanco-Prieto MJ, (2007) Purification of bioactive glycosylated recombinant glial cell line-derived neurotrophic factor. Int J Pharm 344: 9-15.
17. Gearhart DA, Middlemore ML, Terry AV, (2006) ELISA methods to measure cholinergic markers and nerve growth factor receptors in cortex, hippocampus, prefrontal cortex, and basal forebrain from rat brain. J Neurosci Methods 150: 159-173.
18. Carnicella S, Ron D, (2009) GDNF-a potential target to treat addiction. Pharmacol Ther 122: 9-18.
19. Eisch AJ, Bolanos CA, de Wit J, Simonak RD, Pudiak CM, et al. (2003) Brain-derived neurotrophic factor in the ventral midbrain-nucleus accumbens pathway: a role in depression. Biol Psychiatry 54: 994-1005.
20. Murer MG, Yan Q, Raisman-Vozari R, (2001) Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. Prog Neurobiol 63: 71-124.
21. Treat LH, McDannold N, Vykhodtseva N, Zhang Y, Tam K, et al. (2007) Targeted delivery of doxorubicin to the rat brain at therapeutic levels using MRI-guided focused ultrasound. Int J Cancer 121: 901-907.
22. Jordao JF, Ayala-Grosso CA, Markham K, Huang Y, Chopra R, et al. (2010) Antibodies targeted to the brain with image-guided focused ultrasound reduces amyloid-beta plaque load in the TgCRND8 mouse model of Alzheimer's disease. PLoS ONE 5: e10549.
23. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF, (1999) In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285: 1569-1572.
24. Doolittle ND, Miner ME, Hall WA, Siegal T, Jerome E, et al. (2000) Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer 88: 637-647.
25. Chopra R, Vykhodtseva N, Hynynen K, (2010) Influence of exposure time and pressure amplitude on blood-brain-barrier opening using transcranial ultrasound exposures. ACS Chem Neurosci 1: 391-398.
26. Wang F, Cheng Y, Mei J, Song Y, Yang YQ, et al. (2009) Focused ultrasound microbubble destruction-mediated changes in blood-brain barrier permeability assessed by contrast-enhanced magnetic resonance imaging. J Ultrasound Med 28: 1501-1509.
27. McDannold N, Vykhodtseva N, Hynynen K, (2008) Effects of acoustic parameters and ultrasound contrast agent dose on focused-ultrasound induced blood-brain barrier disruption. Ultrasound Med Biol 34: 930-937.
28. Kinoshita M, McDannold N, Jolesz FA, Hynynen K, (2006) Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption. Proc Natl Acad Sci U S A 103: 11719-11723.
29. Hernot S, Klibanov AL, (2008) Microbubbles in ultrasound-triggered drug and gene delivery. Adv Drug Deliv Rev 60: 1153-1166.
30. Lum AF, Borden MA, Dayton PA, Kruse DE, Simon SI, et al. (2006) Ultrasound radiation force enables targeted deposition of model drug carriers loaded on microbubbles. J Control Release 111: 128-134.